Literature DB >> 3955552

Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.

S D Williams, R Birch, L H Einhorn.   

Abstract

Twenty-two evaluable patients with all cell types of advanced thyroid cancer were treated with the combination of doxorubicin (60 mg/m2) plus cisplatin (60 mg/m2). There were two brief partial remissions (9.1%). There was considerable toxicity, with one drug-related death. Combination chemotherapy as given in this study was not effective for this patient population.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3955552

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  26 in total

Review 1.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.

Authors:  P De Besi; B Busnardo; S Toso; M E Girelli; D Nacamulli; N Simioni; D Casara; P Zorat; M V Fiorentino
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

3.  Candidate agents for papillary thyroid cancer identified by gene expression analysis.

Authors:  Wei Zhu; Chen Li; Zhilong Ai
Journal:  Pathol Oncol Res       Date:  2013-03-22       Impact factor: 3.201

4.  Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.

Authors:  H Scherübl; F Raue; R Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 5.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

Review 6.  Treatment of distant metastases of differentiated thyroid carcinoma.

Authors:  M Schlumberger; C Challeton; F De Vathaire; C Parmentier
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

7.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

8.  2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

Authors:  M Schlumberger; L Bastholt; H Dralle; B Jarzab; F Pacini; J W A Smit
Journal:  Eur Thyroid J       Date:  2012-03-28

9.  Targeted therapies in thyroid cancer.

Authors:  Jaume Capdevila; Jose Perez-Garcia; Gabriel Obiols; Josep Tabernero
Journal:  Target Oncol       Date:  2009-11-11       Impact factor: 4.493

10.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.